The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

NCT01738035 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

DRUG: NEFECON
OTHER: Placebo

Sponsor

Calliditas Therapeutics AB